The MC1R melanoma risk variant p.R160W is associated with Parkinson disease

Annals of Neurology

Volumn 77, Issue 5, 2015, Pages 889-894

  Tell Marti, Gemma ^a,b   Puig Butille, Joan Anton ^a   Potrony, Miriam ^a   Badenas, Celia ^a,b   Milà, Montserrat ^a,b   Malvehy, Josep ^a,b   Martí, María José ^c   Ezquerra, Mario ^c   Fernández Santiago, Rubén ^c   Puig, Susana ^a,b,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOCORTIN 1 RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAIR COLOR; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; PARKINSON DISEASE; PHENOTYPE; PIGMENTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SPAIN; AGED; AMINO ACID SEQUENCE; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MOLECULAR GENETICS; PROCEDURES;

ADULT; AGED; AMINO ACID SEQUENCE; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PARKINSON DISEASE; RECEPTOR, MELANOCORTIN, TYPE 1; SPAIN;

EID: 84928203520     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24373     Document Type: Article

References (24)

1. Driver JA,. Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. Biogerontology 2014; 15: 547-557.
2. Bajaj A, Driver JA, Schernhammer ES,. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010; 21: 697-707.
3. Liu R, Gao X, Lu Y, Chen H,. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011; 76: 2002-2009.
4. Olsen JH, Tangerud K, Wermuth L, et al. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007; 22: 1252-1257.
5. Baade PD, Herrero Hernandez E, Freedman DM, et al. No role for melanoma treatment in the association between melanoma and amyotrophic lateral sclerosis or Parkinson's disease. Neuroepidemiology 2010; 35: 303-304.
6. Rugbjerg K, Harris MA, Shen H, et al. Pesticide exposure and risk of Parkinson's disease-a population-based case-control study evaluating the potential for recall bias. Scand J Work Environ Health 2011; 37: 427-436.
7. Wright Willis A, Evanoff BA, Lian M, et al. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 2010; 34: 143-151.
8. Duffy DL, Zhao ZZ, Sturm RA, et al. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010; 130: 520-528.
9. Gao X, Simon KC, Han J, et al. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol 2009; 65: 76-82.
10. Puig-Butille JA, Escamez MJ, Garcia-Garcia F, et al. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget 2014; 5: 1439-1451.
11. Raimondi S, Sera F, Gandini S, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008; 122: 2753-2760.
12. Williams PF, Olsen CM, Hayward NK, Whiteman DC,. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011; 129: 1730-1740.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ,. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
14. Chaudru V, Laud K, Avril MF, et al. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 2005; 14: 2384-2390.
15. Sole X, Guino E, Valls J, et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928-1929.
16. Dong J, Gao J, Nalls M, et al. Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. Neurobiol Aging 2014; 35: 1512.e5-1512.e10.
17. Gerstenblith MR, Goldstein AM, Fargnoli MC, et al. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 2007; 28: 495-505.
18. Garcia-Borron JC, Abdel-Malek Z, Jimenez-Cervantes C,. MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation. Pigment Cell Melanoma Res 2014; 27: 699-720.
19. Catania A,. Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci 2008; 31: 353-360.
20. Smith AG, Luk N, Newton RA, et al. Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. J Biol Chem 2008; 283: 12564-12570.
21. Low D, Chen KS,. Genome-wide gene expression profiling of the Angelman syndrome mice with Ube3a mutation. Eur J Hum Genet 2010; 18: 1228-1235.
22. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A 1998; 95: 4013-4018.
23. Chu Y, Le W, Kompoliti K, et al. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 2006; 494: 495-514.
24. Nussbaum RL, Ellis CE,. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003; 348: 1356-1364.